Sentences with phrase «virus challenge studies»

«Experimental dengue vaccine protects all recipients in virus challenge study.»

Not exact matches

Vaccinating pregnant mothers year - round against flu in the resource - challenged region of subtropical Nepal reduced infant flu virus infection rates by an average of 30 percent, increased birth weights by 15 percent and resulted in babies having less influenza, according to a study published in The Lancet Infectious Diseases.

While it is challenging to assess the overall impact on the population of such a wide ranging and elusive big cat, the virus contributed to the decline of one well - studied sub-population, which went from 38 individuals to 9 between the years 2007 and 2012.

Led by Bavari and Travis Warren, Ph.D., the USAMRIID team performed a series of studies involving a lethal challenge with Marburg virus in nonhuman primates to determine the efficacious dose and regimen of AVI - 7288, as well as to characterize the drug exposures in animals that produced efficacy.

The United States has sufficient capacity for treating another outbreak of the Ebola virus, but financial, staffing and resource challenges remain a hurdle for many hospitals and health systems attempting to maintain dedicated treatment centers for highly infectious diseases, according to new study released today.

In a study to be published in the July issue of the journal Current Opinion in HIV and AIDS, Dr. Rourke noted that aging for people with HIV may be more challenging than for the general population because of HIV - related stigma, loss of friends and social networks, and the detrimental health effects of the virus and medications taken to combat the virus.

A new study led by scientists at Beth Israel Deaconess Medical Center (BIDMC) shows that an HIV - 1 vaccine regimen, involving a viral vector boosted with a purified envelope protein, provided complete protection in half of the vaccinated non-human primates (NHPs) against a series of six repeated challenges with simian immunodeficiency virus (SIV), a virus similar to HIV that infects NHPs.

The work corroborates a study published in January by a team at University College London, the first to challenge the mouse virus hypothesis.

Specifically, 1 unit of access comprising a vaccination / challenge study with 3 groups of 6 ferrets (control and 2 vaccine groups), to include vaccination / boost, intra-nasal challenge with influenza virus, monitoring of virus load (nasal washes), disease progression and immune responses (antibody, IFN gamma ELISA and ELISpot).

Deep Sequencing of Influenza A Virus from a Human Challenge Study Reveals a Selective Bottleneck and Only Limited Intrahost Genetic Diversification.

The immunopathology in all experiments in the present study occurred in the absence of detectable virus in lungs of mice two days after challenge with infectious virus.

A new study challenges the tenet that herpes viruses, like most enveloped viruses, are relatively unstable outside their host.

HPV is challenging to culture and grow in the lab, so researchers who study the virus use one of three stand - ins made up of one or both types of capsid proteins.

A preclinical study in mice, published earlier this week in Nature, showed that a single dose of ZPIV generated an immune response, which protected the mice against subsequent Zika challenge with a Brazilian strain of the virus.

Studying the link between Zika and GBS has been challenging because other viral illnesses, including the one caused by closely - related dengue virus, also cause GBS.

Genome sequencing has become a powerful tool for studying emerging infectious diseases; however, genome sequencing directly from clinical samples without isolation remains challenging for viruses such as Zika, where metagenomic sequencing methods may generate insufficient numbers of viral reads.

The unit of access comprises a vaccination / challenge study with 3 groups of 6 ferrets (control and 2 vaccine groups), to include intra-nasal challenge with influenza virus, monitoring of virus load (nasal washes), disease progression and immune responses (antibody, IFN gamma ELISA and ELISpot).

Challenge studies have demonstrated that FluSure XP helps provide cross-protection against five clusters or subclusters of H1 viruses, plus H3N2.1 - 7

In a pivotal efficacy study, dogs receiving the Vanguard CIV H3N2 / H3N8 vaccine were protected from disease after CIV H3N2 challenge.2, 3,4 Vaccination also appeared to help decrease the number of days after challenge that dogs shed CIV H3N2 virus — from an average of 4.9 days in the placebo - vaccinated controls to an average of 1.3 days in Vanguard CIV H3N2 / H3N8 vaccinates.2, 5,6

In clinical research studies of the one - and two - dose protocols, Fostera PCV MH has been demonstrated to aid in preventing viremia, lymphoid depletion and colonization of lymphoid tissue caused by PCV2; and as an aid in reducing PCV2 virus shedding and enzootic pneumonia caused by M. hyo.1 - 4 In a real - world, dual - challenge study, Fostera PCV MH helped demonstrate effective control of PCVAD and helped reduce PCV2 viremia in vaccinated pigs, allowing those pigs to sustain favorable growth.5 Pigs vaccinated with Fostera PCV MH exhibited improved average daily gain (ADG) up to 4.5 % (tracked from processing to market) compared with the control group.

«This information would have to be gained by challenge studies in which you give viruses to animals inoculated over five to 10 years ago,» she says.

The only really reliable way to tell how long a vaccine will provide protection is to do challenge studies — to vaccinate a group of dogs and then expose them to the virus after specified intervals, to determine how long the vaccine will provide protection.

The percentage of vaccinated animals (those vaccinated only as puppies) protected from clinical disease after challenge with canine distemper virus, canine parvovirus and canine adenovirus in the study was greater than 95 %.»

«In our studies, puppies vaccinated annually with modified live CPV - 2, CDV and CAV vaccines received no added benefit from annual revaccination throughout a period of 7 years when compared to dogs that were vaccinated as puppies then challenged with virulent virus at 7 years of age.

Several interventions have been demonstrated to be effective in reducing the prevalence of behaviors that place adolescents at risk for acquisition of human immunodeficiency virus (HIV).1 — 6 These programs have in common a small - group and face - to - face method of delivery, an emphasis on skills development referent to decision making, communication, negotiation and condom use, use of a wide variety of instructional formats and approaches to intervention delivery, and grounding in social learning theory.2 — 6 Despite the encouraging results that accompany these studies with reference to adolescent risk reduction, new challenges have emerged.